



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



Ref.: ISLL:CH:2023

Date: 29<sup>th</sup> May, 2023

The President,  
Corporate Relationship Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400001

The Vice President,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400051

ISIN: INE915B01019, INE915B07024  
BSE Scrip Code: 532305, 957989

NSE Symbol: INDSWFTLAB

**Subject: Press Release- Standalone and Consolidated Financial Results for the year ended on 31<sup>st</sup> March, 2023**

Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we are enclosing herewith a press release on the captioned subject, the content of which is self-explanatory.

You are requested to kindly take the same on record.

With Regards,  
For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA**  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY



# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



## PRESS RELEASE ON ANNUAL FINANCIAL RESULTS

**RECORDED NET PROFIT OF RS. 42.47 CRORES AGAINST LOSS OF 5.71 CRORES (YOY)  
REPORTED ALL TIME HIGH EBIDTA OF RS. 250 CRORES**

Ind-Swift Laboratories Limited ( ISLL) has today declared its Financial results for the quarter and financial year ended 31<sup>st</sup> March , 2023 .

On an Annual basis ISLL reported a turnover of Rs. 1178.66 crores as on 31st March 2023, as against turnover of Rs. 1016.61 crores as on 31st March 2022, registering a growth of 15.94%. The net profit of the Company rose from the net loss of Rs. 5.71 crores during 2021-22 to net profit of Rs. 42.47 crores during the Financial year 2022-23. The Company closed the financial year with a life time highest EBIDTA level of Rs. 250 crores , up by 5.92% from the EBIDTA of the financial year 2021-22.

On a Quarterly basis the ISLL reported a turnover of Rs. 294.81 crores during the quarter ended 31st March 2023, as against turnover of Rs. 285.16 crores during the quarter ended 31st March 2022, registering a growth of 4%. The Company has however reported net loss during the quarter of Rs. 30.91 crores as against the net loss of Rs. 63.18 crores during the quarter ended 31<sup>st</sup> March 2022. The net loss is majorly attributable to the one time loss on sale of investment during the quarter due to which the company recorded a loss of Rs. 26.64 crores. The Company however reported an EBIDTA of Rs. 61.72 crores during the quarter ended 31<sup>st</sup> March, 2023, which is very much in line with the performance of the Company for the last 6 to 8 quarters.

Commenting on the results Sh. N.R.Munjhal, Chairman and Managing Director of Ind-Swift Laboratories Limited stated that “ The year 2022-23 has been a significant year in the history of the Company as the Company reported lifetime high EBIDTA of Rs. 250 crores ; the performance of the company had been par excellence.”

Company has seen good demand for its products. The molecules like Clarithromycin, Clarithromycin granules , Fexofenadine , Ezetimibe, Quetiapine Fumerate and Donepezil gave more than 20% growth on an average during the year. The volumes on an overall basis also grew by more than 5% . The Exports of the Company grew by more than 18% from a sum of Rs. 745 crores to Rs. 886 crores. Company exports its products to more than 70 countries across the globe.

Giving overall outlook for the financial year 2023-24, Mr. Munjal expressed that “ We expect the overall growth to continue in the current fiscal also and expect the topline and bottomline to grow by 10%-15% . He further explained that presently the Company is reinforcing its position by utilising the additional cash towards reducing its overall debt and that is the reason, the Board has not considered declaring any dividend during the year; going forward we are hopeful to reward the shareholders for their faith and confidence in the management and the Company”





# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : [info@indswiflabs.com](mailto:info@indswiflabs.com) Website : [www.indswiflabs.com](http://www.indswiflabs.com)  
CIN No. L24232CH1995PLC015553



The Earning per share of the Company rose by 865% from Rs. -0.97 as on 31<sup>st</sup> March 2022 to Rs. 7.43 as on 31<sup>st</sup> March 2023.

Ind-Swift Laboratories Limited is one of the largest producer of APIs and Advanced intermediates in North India with one of the largest manufacturing facility and capacities . The Company earns over 70%of its revenues from Exports. The company has accreditations from all the Regulatory Bodies of the World like USFDA, EDQM, PMDA, ANVISA, Cofeporis, TGA,WHO.

Ind-Swift Laboratories Limited was recently awarded with “Asia’s Best Company of the Year-2022” award by Berkshire Media LLC, USA on their Annual Awarding Ceremony held at Hotel Grand Hyatt Erawan, Bangkok, Thailand. Berkshire Media is a multinational brand consulting & a market research firm headquartered in USA. Berkshire conducts independent research on spread, reach and market presence of organizations across world and they declare awards in respective categories based on their multi-factored studies. Last year ISLL was also conferred with award of “North India’s Best Employer Brand-2021” by World HRD Congress.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

**PARDEEP VERMA**  
**VP-CORPORATE AFFAIRS AND COMPANY SECRETARY**  
**E.MAIL : [pardeep.verma@indswiflabs.com](mailto:pardeep.verma@indswiflabs.com)**

